Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX in metastatic breast cancer
NCT00274859Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Aug 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and oxaliplatin in breast cancer, sponsored by GERCOR. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00274859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274859.